National Centre for Pharmacoeconomics

National Centre for
Pharmacoeconomics

NCPE Ireland

House Dust Mite extract (Acarizax®) is indicated in adult patients (18-65 years) diagnosed by clinical history and a positive test of HDM sensitisation (skin prick test and/or specific IgE) with persistent moderate to severe house dust mite allergic rhinitis despite use of symptom-relieving medication.

 

NCPE Assessment Process Complete
Rapid review commissioned 12/03/2020
Rapid review completed 30/04/2020
Rapid Review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of HDM extract (Acarizax ®) compared with the current standard of care.